RT期刊文章SR电子T1等离子体在苏氨酸磷酸化τ181和神经精神症状的临床前和前驱的阿尔茨海默病摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP e683 OP e693 10.1212 / WNL。首页100签证官0000000000201517是7 A1 Maryam Ghahremani A1王濛A1庄志渊陈A1 Henrik Zetterberg A1埃里克史密斯A1 Zahinoor伊斯梅尔A1的阿尔茨海默病的神经影像学*年2023 UL //www.ez-admanager.com/content/100/7/e683.abstract AB背景和目标等离子体在苏氨酸磷酸化τ181 (p-tau181)首页,经阿尔茨海默病(AD)病理变化的标志,可以更有效的方式来诊断广告比入侵或昂贵的生物标志物需要CSF或宠物。在某些个人、神经精神症状(NPS)是最早的广告表现形式,提前观察到清晰的认知能力下降。,然而,很少有研究评估广告生物标志物与NPS经常有不精确捕捉行为症状代表神经退行性疾病的后遗症。因此,轻度行为障碍(MBI)构建了框架NPS在某种程度上改善疾病的风险估计的精度。MBI核心标准规定,NPS新创出现在以后的生活和持续至少6个月。这里,横向比较和纵向,我们研究协会与p-tau181 MBI,神经心理测试性能和事件的广告。方法认知没有和轻度认知障碍(MCI)的阿尔茨海默病的神经影像学参与者被选中。MBI地位是来源于神经精神病学的库存(NPI)使用发表的算法。NPI总分在基线和第一年访问被用来实施MBI(访问)评分> 0,NPS未满足MBI要求(NPS-not-MBI,分数> 0仅1访问),而且没有NPS(得分= 0在访问)。线性回归是适合横断面分析; multilevel linear mixed-effects and Cox proportional hazards models were implemented to examine the longitudinal associations of MBI with changes in p-tau181 and cognition and incident dementia.Results The sample included 571 participants (age 72.2 years, 46.8% female, 64.8% MCI). Cross-sectionally (β = 8.1%, 95% CI 1.4%–15.2%, p = 0.02), MBI was associated with higher plasma p-tau181 levels compared with no NPS; NPS-not-MBI was not. Longitudinally, MBI was associated with higher p-tau181 (β = 0.014%, 95% CI 0.003–0.026, p = 0.02), in addition to a decline in memory and executive function. Survival analyses demonstrated a 3.92-fold greater dementia incidence in MBI, with no significant differences between NPS-not-MBI and no NPS.Discussion These findings extend the evidence base that MBI is associated with elevated risk of cognitive decline and dementia and a sequela of emerging Alzheimer-related proteinopathies. MBI offers a substantial improvement over current approaches that explore behavior as a proxy marker for Alzheimer-related proteinopathies, with both clinical and AD trial enrichment implications.Aβ=β-amyloid; AD=Alzheimer disease; ADNI=Alzheimer's Disease Neuroimaging Initiative; A/T/N=amyloid/tau/neurodegeneration; CU=cognitively unimpaired; HR=hazard ratio; MBI=mild behavioral impairment; MBI-C=MBI checklist; MLME=multilevel linear mixed effect; MMSE=Mini-Mental State Examination; NfL=neurofilament light; NIA-AA=National Institute of Aging–Alzheimer's Association; NPI=Neuropsychiatric Inventory; NPI-Q=NPI Questionnaire; NPS=neuropsychiatric symptoms; p-tau181=phosphorylated tau at threonine 181; RAVLT=Rey Auditory Verbal Learning Test